| abstract |
Humanized, mouse or chimeric anti-CD47 monoclonal antibodies are provided. The nantibodies bind to human glycosylated and deglycosylated CD47 with an optimized Koff value, nthey disrupt the human CD47-SIRPa interaction, and find use in various therapeutic, preventive nor diagnostic methods. The invention includes isolated antibodies and derivatives and fragments nthereof, pharmaceutical formulations comprising one or more of the humanized or chimeric antinCD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also nprovided are amino acid and nucleotide sequences of the antibodies. |